Key result
MitraClip achieves 80% acute procedural success with no major adverse events.
Observational (n=5)
An initial Egyptian experience demonstrates that percutaneous edge-to-edge mitral valve repair with the MitraClip system is feasible and safe for patients with severe mitral regurgitation.
Answers are grounded in this paper and cite their sources.
Supports feasibility in Egyptian patients; leaves open need for randomized trials before wider adoption.
Objectives To evaluate the feasibility, efficacy, and safety of the MitraClip system in patients with severe MR. Background Mitral valve repair for mitral regurgitation (MR) has been performed by the use of a surgically created double orifice. Percutaneous repair based on this surgical approach has been developed by use of the MitraClip device to secure the mitral leaflets. Methods Five Patients with 3 to 4+ MR were selected in accordance with the American Heart Association/American College of Cardiology guidelines between March 2013 and May 2013 and underwent percutaneous mitral repair with MitraClip system . Patients were followed up for six months after procedure. The primary acute safety endpoint was freedom from major adverse events (MAEs) at 30 days, defined as the composite of death, myocardial infarction, non-elective cardiac surgery for adverse events, renal failure, transfusion of more than 2 units of blood, ventilation for more than 48 h, deep wound infection, septicemia. The primary efficacy endpoint is acute device success defined as clip implant with reduction of MR to equal or less than grade II, based on current guidelines. Results A total of 5 patients were treated. No patients (0%) had a major adverse event,. Freedom from clip embolization was 100%. Partial clip detachment had not occurred in any patients (0%) patients. Overall, 4 of 5 (80%) patients achieved acute procedural success, and 3 (60%) were discharged with MR of ⩽ 1+. Conclusions Our initial results with the MitraClip device in a very small number of patients indicate that percutaneous edge-to edge mitral valve repair is feasible and may be accomplished with favorable short-term safety and efficacy results.
No takes yet. Share an insight, caveat, or question.
Khamis et al. (2014) conducted an observational in severe mitral regurgitation (n=5). MitraClip system was evaluated on Acute device success defined as clip implant with reduction of MR to equal or less than grade II. Percutaneous mitral valve repair using the MitraClip system achieved acute procedural success in 80% of patients, with no major adverse events at 30 days.
Synapse has enriched 10 related papers. Consider them for comparative context: